Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) has a beta value of 0.73 and has seen 1.27 million shares traded in the last trading session. The company, currently valued at $3.49B, closed the last trade at $28.14 per share which meant it lost -$0.14 on the day or -0.50% during that session. The ARWR stock price is -50.96% off its 52-week high price of $42.48 and 26.55% above the 52-week low of $20.67. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.65 million shares traded. The 3-month trading volume is 1.66 million shares.
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) trade information
Sporting -0.50% in the red in last session, the stock has traded in the red over the last five days, when the ARWR stock price touched $28.14 or saw a rise of 4.38%. Year-to-date, Arrowhead Pharmaceuticals Inc. shares have moved -8.04%, while the 5-day performance has seen it change -4.29%. Over the past 30 days, the shares of Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) have changed -4.84%. Short interest in the company has seen 8.84 million shares shorted with days to cover at 5.67.
Arrowhead Pharmaceuticals Inc. (ARWR) estimates and forecasts
Figures show that Arrowhead Pharmaceuticals Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -2.70% over the past 6 months, with this year growth rate of -40.63%, compared to 11.30% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are -135.60% and 34.40% for the next quarter. Revenue growth from the last financial year stood is estimated to be -42.20%.
10 analysts offering their estimates for the company have set an average revenue estimate of $63.87 million for the current quarter. 11 have an estimated revenue figure of $29.52 million for the next quarter concluding in Jun 2024.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -24.19% over the past 5 years. Earnings growth for 2024 is a modest -40.09% while over the next 5 years, the company’s earnings are expected to increase by 7.33%.
ARWR Dividends
Arrowhead Pharmaceuticals Inc. is expected to release its next earnings report between April 30 and May 06 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)’s Major holders
Insiders own 4.47% of the company shares, while shares held by institutions stand at 65.27% with a share float percentage of 68.32%. Investors are also buoyed by the number of investors in a company, with Arrowhead Pharmaceuticals Inc. having a total of 375 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 12.81 million shares worth more than $456.85 million. As of Jun 29, 2023, Blackrock Inc. held 11.95% of shares outstanding.
The other major institutional holder is Vanguard Group Inc, with the holding of over 10.97 million shares as of Jun 29, 2023. The firm’s total holdings are worth over $391.25 million and represent 10.24% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Core S&P Midcap ETF and Vanguard Total Stock Market Index Fund. As of Sep 29, 2023, the former fund manager holds about 3.13% shares in the company for having 3.35 million shares of worth $90.08 million while later fund manager owns 3.23 million shares of worth $115.06 million as of Jun 29, 2023, which makes it owner of about 3.01% of company’s outstanding stock.
